December Reason 5 O O
1, Reason 5 O O
2016 Reason 5 O O
[(Vol. Reason 5 O O
36, Reason 5 O O
No. Reason 5 O O
21)](/category/magazine/283/) Reason 5 O O
Vaccines Reason 5 O O
Are Reason 5 O O
An Reason 5 O O
Important Reason 5 O O
Part Reason 5 O O
of Reason 5 O O
Predictive, Reason 5 O O
Personalized, Reason 5 O O
Preventive Reason 5 O O
and Reason 5 O O
Participatory Reason 5 O O
Medicine Reason 5 O O
Leroy Reason 5 O O
Hood, Reason 5 O O
M.D., Reason 5 O O
Ph.D., Reason 5 O O
president Reason 5 O O
and Reason 5 O O
co-founder Reason 5 O O
of Reason 5 O O
the Reason 5 O O
Institute Reason 5 ScientificAuthority O
for Reason 5 ScientificAuthority O
Systems Reason 5 ScientificAuthority O
Biology, Reason 5 ScientificAuthority O
has Reason 5 O O
predicted Reason 5 O O
that Reason 5 O O
a Reason 5 O O
"new Reason 5 O O
medicine" Reason 5 O O
is Reason 5 O O
coming, Reason 5 O O
some Reason 5 O O
aspects Reason 5 O O
of Reason 5 O O
which Reason 5 O O
are Reason 5 O O
already Reason 5 O O
in Reason 5 O O
their Reason 5 O O
early Reason 5 O O
stages. Reason 5 O O
He O O O O
says O O O O
the O O O O
new O O O O
medicine O O O O
will O O O O
be O O O O
predictive, O O O O
personalized, O O O O
preventive, O O O O
and O O O O
participatory O O O O
(P4). O O O O
"Molecular O O O O
diagnostics O O O O
will O O O O
provide O O O O
the O O O O
tools O O O O
to O O O O
identify O O O O
and O O O O
predict O O O O
disease. O O O O
Systems Reason 5 O O
approaches Reason 5 O O
will Reason 5 O O
generate Reason 5 O O
preventive Reason 5 O O
drugs Reason 5 O O
or Reason 5 O O
vaccines, Reason 5 O O
plus Reason 5 O O
the Reason 5 O O
focus Reason 5 O O
on Reason 5 O O
wellness Reason 5 O O
will Reason 5 O O
be Reason 5 O O
a Reason 5 O O
powerful Reason 5 O O
preventive," Reason 5 O O
according Reason 5 O O
to Reason 5 O O
Dr. Reason 5 O O
Hood. Reason 5 O O
One Reason 5 O O
of Reason 5 O O
the Reason 5 O O
rapidly Reason 5 O O
growing Reason 5 O O
areas Reason 5 O O
of Reason 5 O O
P4 Reason 5 O O
medicine Reason 5 O O
can Reason 5 O O
be Reason 5 O O
found Reason 5 O O
in Reason 5 O O
therapeutic Reason 5 O O
cancer Reason 5 O O
vaccines, Reason 5 O O
a Reason 5 O O
number Reason 5 O O
of Reason 5 O O
which Reason 5 O O
are Reason 5 O O
already Reason 5 O O
undergoing Reason 5 O O
intense Reason 5 O O
R&D Reason 5 O O
and Reason 5 O O
clinical Reason 5 O O
studies. Reason 5 O O
These Reason 5 O O
biological Reason 5 O O
response Reason 5 O O
modifiers, Reason 5 O O
which Reason 5 O O
can Reason 5 O O
be Reason 5 O O
classed Reason 5 O O
as Reason 5 O O
preventive Reason 5 O O
or Reason 5 O O
treatment Reason 5 O O
vaccines, Reason 5 O O
work Reason 5 O O
by Reason 5 O O
stimulating Reason 5 O O
or Reason 5 O O
restoring Reason 5 O O
the Reason 5 O O
immune Reason 5 O O
system's Reason 5 O O
ability Reason 5 O O
to Reason 5 O O
fight Reason 5 O O
infections Reason 5 O O
and Reason 5 O O
disease. Reason 5 O O
GEN Reason 4 O O
spoke Reason 4 O O
to Reason 4 O O
representatives Reason 4 O O
of Reason 4 O O
several Reason 4 O O
companies Reason 4 O O
that Reason 4 O O
are Reason 4 O O
focused Reason 4 O O
on Reason 4 O O
therapeutic Reason 4 O O
cancer Reason 4 O O
vaccines Reason 4 O O
to Reason 4 O O
get Reason 4 O O
a Reason 4 O O
status Reason 4 O O
report Reason 4 O O
on Reason 4 O O
this Reason 4 O O
promising Reason 4 O O
area Reason 4 O O
of Reason 4 O O
P4 Reason 4 O O
medicine. Reason 4 O O
GEN: O O O O
Would O O O O
you O O O O
describe O O O O
your O O O O
specific O O O O
approach O O O O
to O O O O
therapeutic O O O O
cancer O O O O
vaccine O O O O
R&D? O O O O
Dr. Reason 5 O O
Castle: Reason 5 O O
Agenus' Reason 5 O O
approach Reason 5 O O
to Reason 5 O O
cancer Reason 5 O O
vaccines Reason 5 O O
starts Reason 5 O O
with Reason 5 O O
genomics, Reason 5 O O
bioinformatics, Reason 5 O O
and Reason 5 O O
computational Reason 5 O O
immunology. Reason 5 O O
It Reason 5 O O
involves Reason 5 O O
identification Reason 5 O O
and Reason 5 O O
characterization Reason 5 O O
of Reason 5 O O
tumor Reason 5 O O
neoantigens Reason 5 O O
unique Reason 5 O O
to Reason 5 O O
each Reason 5 O O
patient Reason 5 O O
using Reason 5 O O
next-generation Reason 5 O O
sequencing Reason 5 O O
(NGS) Reason 5 O O
for Reason 5 O O
rapid Reason 5 O O
profiling Reason 5 O O
of Reason 5 O O
the Reason 5 O O
mutational Reason 5 O O
signature Reason 5 O O
of Reason 5 O O
the Reason 5 O O
tumor. Reason 5 O O
Advanced Reason 4 O O
bioinformatics Reason 4 O O
algorithms, Reason 4 O O
mass Reason 4 O O
spectrometry, Reason 4 O O
and Reason 4 O O
structural Reason 4 O O
biology Reason 4 O O
modeling Reason 4 O O
analyses Reason 4 O O
are Reason 4 O O
then Reason 4 O O
utilized Reason 4 O O
to Reason 4 O O
determine Reason 4 O O
the Reason 4 O O
antigenic Reason 4 O O
peptide Reason 4 O O
repertoire Reason 4 O O
that Reason 4 O O
arises Reason 4 O O
from Reason 4 O O
these Reason 4 O O
mutations, Reason 4 O O
enabling Reason 4 O O
us Reason 4 O O
to Reason 4 O O
create Reason 4 O O
the Reason 4 O O
so-called Reason 4 O O
vaccine Reason 4 O O
"blueprint." Reason 4 O O
Our Reason 4 O O
vaccine Reason 4 O O
format Reason 4 O O
is Reason 4 O O
based Reason 4 O O
on Reason 4 O O
heat Reason 4 O O
shock Reason 4 O O
protein Reason 4 O O
(HSP) Reason 4 O O
Hsc70, Reason 4 O O
which Reason 4 O O
in Reason 4 O O
addition Reason 4 O O
to Reason 4 O O
our Reason 4 O O
adjuvant Reason 4 O O
QS-21 Reason 4 O O
StimulonÂ® Reason 4 O O
enhances Reason 4 O O
immunogenicity. Reason 4 O O
Dr. Reason 4 O O
Nejadnik: Reason 4 O O
Galena Reason 4 O O
has Reason 4 O O
in-licensed Reason 4 O O
its Reason 4 O O
cancer Reason 4 O O
vaccine Reason 4 O O
assets. Reason 4 O O
Most O O O O
therapeutic O O O O
agents O O O O
are O O O O
focused O O O O
on O O O O
treatment O O O O
of O O O O
advanced O O O O
cancer, O O O O
but O O O O
rarely O O O O
on O O O O
the O O O O
prevention O O O O
of O O O O
recurrence O O O O
in O O O O
an O O O O
adjuvant O O O O
setting O O O O
once O O O O
a O O O O
patient O O O O
is O O O O
clinically O O O O
diagnosed O O O O
as O O O O
"disease O O O O
free." O O O O
This O O O O
leaves O O O O
a O O O O
significant O O O O
area O O O O
of O O O O
unmet O O O O
medical O O O O
need O O O O
where O O O O
Galena O O O O
is O O O O
targeting O O O O
within O O O O
its O O O O
development O O O O
programs. O O O O
The O O O O
company O O O O
is O O O O
developing O O O O
its O O O O
programs O O O O
as O O O O
single O O O O
agents O O O O
and O O O O
also O O O O
is O O O O
poised O O O O
to O O O O
push O O O O
forward O O O O
with O O O O
combination O O O O
immunotherapy, O O O O
in O O O O
more O O O O
advanced O O O O
disease, O O O O
which O O O O
is O O O O
the O O O O
focus O O O O
of O O O O
great O O O O
interest O O O O
in O O O O
cancer O O O O
treatment. O O O O
Dr. O O O O
Swanson: O O O O
Clinically O O O O
in O O O O
glioblastoma, O O O O
we O O O O
leverage O O O O
the O O O O
power O O O O
of O O O O
a O O O O
patient's O O O O
immune O O O O
system O O O O
by O O O O
treatment O O O O
with O O O O
autologous O O O O
dendritic O O O O
cells, O O O O
primed O O O O
with O O O O
cancer O O O O
stem O O O O
cell O O O O
antigens. O O O O
Careful O O O O
selection O O O O
of O O O O
target O O O O
antigens O O O O
induces O O O O
a O O O O
focused O O O O
cytotoxic O O O O
T-cell O O O O
response O O O O
that O O O O
can O O O O
eliminate O O O O
residual O O O O
tumor O O O O
remaining O O O O
after O O O O
debulking. O O O O
This O O O O
approach O O O O
can O O O O
educate O O O O
the O O O O
immune O O O O
system O O O O
to O O O O
provide O O O O
long-term O O O O
surveillance O O O O
preventing O O O O
tumor O O O O
recurrence. O O O O
We O O O O
have O O O O
a O O O O
novel O O O O
Stem-to-T-cell O O O O
approach O O O O
in O O O O
research O O O O
designed O O O O
to O O O O
drive O O O O
some O O O O
of O O O O
the O O O O
patients' O O O O
hematopoietic O O O O
stem O O O O
cells O O O O
into O O O O
generating O O O O
T O O O O
cells O O O O
directed O O O O
against O O O O
a O O O O
specific O O O O
tumor O O O O
antigen. O O O O
We O O O O
are O O O O
also O O O O
developing O O O O
ways O O O O
to O O O O
improve O O O O
dendritic O O O O
cell O O O O
immunotherapies. O O O O
Dr. O O O O
Lam: O O O O
Immunophotonics O O O O
is O O O O
developing O O O O
an O O O O
in O O O O
situ O O O O
autologous O O O O
cancer O O O O
vaccine O O O O
called O O O O
inCVAX, O O O O
"in-SEE-vax." O O O O
It Reason 4 O O
is Reason 4 O O
a Reason 4 O O
two-step Reason 4 O O
procedure Reason 4 O O
that Reason 4 O O
generates Reason 4 O O
the Reason 4 O O
therapeutic Reason 4 O O
vaccine Reason 4 O O
inside Reason 4 O O
the Reason 4 O O
patient's Reason 4 O O
body Reason 4 O O
using Reason 4 O O
his/her Reason 4 O O
own Reason 4 O O
tumor. Reason 4 O O
First O O O O
a O O O O
palpable O O O O
tumor O O O O
is O O O O
primed O O O O
using O O O O
a O O O O
thermal O O O O
gradient O O O O
to O O O O
liberate O O O O
tumor O O O O
neoantigens. O O O O
Next, O O O O
an O O O O
intratumoral O O O O
injection O O O O
of O O O O
our O O O O
immunostimulant O O O O
GC O O O O
promotes O O O O
an O O O O
adaptive O O O O
immune O O O O
response. O O O O
Our O O O O
initial O O O O
nonclinical O O O O
and O O O O
clinical O O O O
studies O O O O
suggest O O O O
that O O O O
inCVAX O O O O
is O O O O
capable O O O O
of O O O O
eliminating O O O O
primary O O O O
tumors O O O O
and O O O O
metastases. O O O O
Immunophotonics O O O O
has O O O O
initiated O O O O
a O O O O
randomized, O O O O
controlled O O O O
breast O O O O
cancer O O O O
clinical O O O O
trial O O O O
for O O O O
inCVAX O O O O
and O O O O
continues O O O O
to O O O O
study O O O O
the O O O O
treatment O O O O
in O O O O
a O O O O
variety O O O O
of O O O O
nonclinical O O O O
models. O O O O
Dr. O O O O
Ang: O O O O
Neon O O O O
Therapeutics O O O O
is O O O O
focused O O O O
on O O O O
using O O O O
neoantigen-based O O O O
targets O O O O
in O O O O
its O O O O
cancer O O O O
vaccines. O O O O
Neoantigen O O O O
targets O O O O
are O O O O
inherently O O O O
tumor-specific, O O O O
should O O O O
not O O O O
be O O O O
subject O O O O
to O O O O
central O O O O
tolerance, O O O O
and, O O O O
as O O O O
non-native O O O O
sequences, O O O O
are O O O O
thought O O O O
to O O O O
be O O O O
far O O O O
more O O O O
immunogenic O O O O
than O O O O
tumor-associated O O O O
antigen O O O O
targets. O O O O
Since O O O O
neoantigens O O O O
are O O O O
generally O O O O
unique O O O O
and O O O O
specific O O O O
to O O O O
each O O O O
tumor O O O O
and O O O O
patient, O O O O
one O O O O
approach O O O O
is O O O O
to O O O O
create O O O O
a O O O O
fully O O O O
individualized O O O O
treatment O O O O
requiring O O O O
tumor O O O O
and O O O O
normal O O O O
tissue O O O O
sequencing, O O O O
mutation O O O O
calling, O O O O
epitope O O O O
selection O O O O
and O O O O
design, O O O O
and O O O O
ultimately O O O O
individualized O O O O
manufacturing O O O O
to O O O O
create O O O O
a O O O O
bespoke O O O O
medicine O O O O
for O O O O
each O O O O
patient. O O O O
Separately, O O O O
Neon O O O O
is O O O O
researching O O O O
shared O O O O
neoantigen O O O O
targets, O O O O
which O O O O
could O O O O
be O O O O
used O O O O
for O O O O
off-the-shelf O O O O
vaccine O O O O
products. O O O O
GEN: O O O O
What O O O O
are O O O O
some O O O O
major O O O O
hurdles O O O O
that O O O O
need O O O O
to O O O O
be O O O O
overcome O O O O
in O O O O
developing O O O O
an O O O O
effective O O O O
cancer O O O O
vaccine? O O O O
Dr. Reason 2 O O
Castle: Reason 2 O O
A Reason 2 O O
number Reason 2 O O
of Reason 2 O O
challenges Reason 2 O O
are Reason 2 O O
associated Reason 2 O O
with Reason 2 O O
individualized Reason 2 O O
vaccines: Reason 2 O O
collecting Reason 2 O O
high-quality Reason 2 O O
tumor Reason 2 O O
material, Reason 2 O O
tumor Reason 2 O O
heterogeneity, Reason 2 O O
the Reason 2 O O
speed Reason 2 O O
of Reason 2 O O
obtaining Reason 2 O O
the Reason 2 O O
tumor Reason 2 O O
fingerprint Reason 2 O O
using Reason 2 O O
NGS, Reason 2 O O
identification Reason 2 O O
of Reason 2 O O
targets Reason 2 O O
that Reason 2 O O
are Reason 2 O O
most Reason 2 O O
immunogenic, Reason 2 O O
and Reason 2 O O
the Reason 2 O O
speed Reason 2 O O
of Reason 2 O O
"on-demand" Reason 2 O O
manufacturing. Reason 2 O O
When Reason 2 O O
it Reason 2 O O
comes Reason 2 O O
to Reason 2 O O
off-the-shelf Reason 2 O O
vaccines, Reason 2 O O
determining Reason 2 O O
target Reason 2 O O
prevalence Reason 2 O O
for Reason 2 O O
each Reason 2 O O
indication Reason 2 O O
and Reason 2 O O
ensuring Reason 2 O O
that Reason 2 O O
that Reason 2 O O
target Reason 2 O O
is Reason 2 O O
not Reason 2 O O
expressed Reason 2 O O
in Reason 2 O O
normal Reason 2 O O
healthy Reason 2 O O
tissues Reason 2 O O
are Reason 2 O O
key Reason 2 O O
hurdles. Reason 2 O O
Vaccine Reason 3 O O
format Reason 3 O O
and Reason 3 O O
adjuvant Reason 3 O O
choice Reason 3 O O
are Reason 3 O O
also Reason 3 O O
important Reason 3 O O
considerations. Reason 3 O O
Lastly, Reason 2 O O
determining Reason 2 O O
which Reason 2 O O
immunomodulatory Reason 2 O O
antibodies Reason 2 O O
pair Reason 2 O O
well Reason 2 O O
with Reason 2 O O
vaccines Reason 2 O O
and Reason 2 O O
optimizing Reason 2 O O
dosing Reason 2 O O
schedules, Reason 2 O O
both Reason 2 O O
in Reason 2 O O
the Reason 2 O O
context Reason 2 O O
of Reason 2 O O
monotherapy Reason 2 O O
and Reason 2 O O
combination Reason 2 O O
therapy, Reason 2 O O
present Reason 2 O O
additional Reason 2 O O
challenges. Reason 2 O O
Dr. O O O O
Nejadnik: O O O O
The O O O O
immune O O O O
system O O O O
consists O O O O
of O O O O
complex O O O O
and O O O O
interdependent O O O O
elements. O O O O
It O O O O
functions O O O O
though O O O O
a O O O O
combination O O O O
of O O O O
immune O O O O
activation O O O O
and O O O O
tolerance O O O O
pathways O O O O
in O O O O
a O O O O
physiological O O O O
satiation O O O O
and O O O O
even O O O O
more O O O O
sophisticated O O O O
in O O O O
pathological O O O O
situation. O O O O
Vaccination Reason 5 O O
is Reason 5 O O
the Reason 5 O O
ultimate Reason 5 O O
active Reason 5 O O
immunotherapy Reason 5 O O
for Reason 5 O O
preventing Reason 5 O O
recurrence Reason 5 O O
or Reason 5 O O
slowing Reason 5 O O
down Reason 5 O O
the Reason 5 O O
disease Reason 5 O O
progression. Reason 5 O O
It O O O O
is O O O O
difficult O O O O
to O O O O
predict O O O O
the O O O O
direct O O O O
cause O O O O
and O O O O
effect O O O O
in O O O O
immunotherapy O O O O
and O O O O
even O O O O
more O O O O
in O O O O
the O O O O
case O O O O
of O O O O
cancer O O O O
where O O O O
immune O O O O
tolerance O O O O
has O O O O
settled O O O O
and O O O O
the O O O O
cancer O O O O
has O O O O
broken O O O O
though O O O O
the O O O O
immune O O O O
defenses. O O O O
There Reason 5 O O
is Reason 5 O O
a Reason 5 O O
growing Reason 5 O O
consensus Reason 5 O O
that Reason 5 O O
combination Reason 5 O O
therapies, Reason 5 O O
including Reason 5 O O
vaccination, Reason 5 O O
may Reason 5 O O
yield Reason 5 O O
the Reason 5 O O
greatest Reason 5 O O
clinical Reason 5 O O
benefit. Reason 5 O O
Dr. O O O O
Swanson: O O O O
Harnessing O O O O
the O O O O
extraordinary O O O O
power O O O O
of O O O O
the O O O O
immune O O O O
system O O O O
to O O O O
battle O O O O
tumors O O O O
could O O O O
revolutionize O O O O
oncology O O O O
treatment. O O O O
To O O O O
fully O O O O
benefit O O O O
from O O O O
immunotherapies, O O O O
it O O O O
is O O O O
critical O O O O
to O O O O
improve O O O O
efficacy O O O O
against O O O O
larger O O O O
tumor O O O O
burden O O O O
while O O O O
still O O O O
protecting O O O O
patient O O O O
safety. O O O O
Autologous O O O O
treatments O O O O
have O O O O
the O O O O
benefit O O O O
of O O O O
safety, O O O O
and O O O O
improvements O O O O
are O O O O
under O O O O
way O O O O
to O O O O
make O O O O
them O O O O
more O O O O
efficacious O O O O
